Latest / Stock Movers / Canada Goose Falls, Celsius Rises, Moderna Slides
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The.
- 0:08Speaker 2: Stock Movers podcast, your roundup of companies making moves in
- 0:13Speaker 2: the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 1: Well, let's take a look at some stocks on the
- 0:18Speaker 1: move today. We got with us Bloomberg News cross ass
- 0:20Speaker 1: that reported Tanita Sikova here on Monday's Stock Movers. What's
- 0:25Speaker 1: on your radar?
- 0:26Speaker 3: Let's start with kind of Goose because I think it's
- 0:27Speaker 3: a really good gouch of retail sentiment, of tariffs, the
- 0:31Speaker 3: consumer and all that. It actually had a pretty rough
- 0:34Speaker 3: start of the day, was down as much as nine percent,
- 0:36Speaker 3: some of the gains were off by the end of
- 0:40Speaker 3: the day, were down just three point five at the close.
- 0:44Speaker 3: Still the stock is down twenty percent here today. So
- 0:47Speaker 3: what's happening is Barclay's actually cut their rating to underweight.
- 0:52Speaker 3: We also had a report from Goldman Sachs saying that
- 0:55Speaker 3: kind of the Goose will be the worst hit, one
- 0:57Speaker 3: of the worst hit retail stocks, and they're estimating about
- 1:01Speaker 3: eighty percent of their sourcing is from KINDAA, So you
- 1:04Speaker 3: can imagine with the tires that will be a big hit. Obviously,
- 1:07Speaker 3: that's a little bit harder and consumer.
- 1:10Speaker 1: Some American geese.
- 1:11Speaker 4: I'm just throw maybe an American brand is coming, I
- 1:14Speaker 4: don't know, or maybe yeah. So the stock is under
- 1:19Speaker 4: a lot of pressure, and this is the second down
- 1:21Speaker 4: grade by Bartley's and there is only one analyst that
- 1:24Speaker 4: has a by rating on kind of the Goose.
- 1:26Speaker 3: So there is al much bullishness.
- 1:28Speaker 1: You know, I walk by Carol Master's desk and it's
- 1:30Speaker 1: it's not even possible to put anything down there because
- 1:33Speaker 1: there's just cans of Celsius all over her desk. She's
- 1:37Speaker 1: just mainlining this stuff shotguns.
- 1:39Speaker 5: That explains everything that everything so not true, but go ahead. Well,
- 1:45Speaker 5: they are building up their female audience because that's the
- 1:48Speaker 5: fastest growing segments because men drinking energy drinks are going
- 1:53Speaker 5: to flatline or decline, but the growth is coming from
- 1:56Speaker 5: women and that's why Celsia has gained seven percent today.
- 2:00Speaker 5: We obviously heard about their acquisition about align New, but
- 2:03Speaker 5: today they got upgraded to buy from Truist, and clearly
- 2:08Speaker 5: the bullishness is because of the acquisition. The price target
- 2:11Speaker 5: is now forty five dollars, up from ten percent.
- 2:15Speaker 3: The space is very competitive. Saleses was down fifty percent
- 2:18Speaker 3: last year. You know, they're competing with red Bue. Everyone
- 2:21Speaker 3: is trying to have like a healthier drink with leash
- 2:24Speaker 3: sugar to attract different audience. But what salesis is doing
- 2:28Speaker 3: so far this year is working. The stock is up
- 2:31Speaker 3: thirty five percent. Yeah, not true, Shelby, right, yeah, yeah.
- 2:34Speaker 3: Vaccine stocks, we've talked about this too. We saw certainly
- 2:37Speaker 3: hitting this session today. We saw a big hit and
- 2:40Speaker 3: we saw a lot of reactions from analysts. So the
- 2:43Speaker 3: biggest loser today is Moderna, which closed nine percent lower,
- 2:48Speaker 3: but it fell as much as fourteen percent. If we
- 2:51Speaker 3: look at the ear today's move, we're talking about a
- 2:54Speaker 3: thirty percent loss. What of course happened today is all
- 2:58Speaker 3: those stocks plunge after Peter Mark's a key figure overseeing
- 3:03Speaker 3: review approver vaccines at the a FDA, resigned and the
- 3:08Speaker 3: reason is, of course, the clash he had with Robert F. Kennedy.
- 3:13Speaker 3: We saw really negative reactions from analysts to the point
- 3:17Speaker 3: where counterfeitsal art. Analysts are slamming their leadership, the leadership
- 3:21Speaker 3: of Kennedy, and saying that the administration should reevaliate that
- 3:25Speaker 3: they're not talking about the stocks. Obviously everyone's saying that's
- 3:28Speaker 3: going to weigh a lot on the stocks, but they're
- 3:30Speaker 3: talking about changing leadership.
- 3:32Speaker 1: So that's what I think is so interesting. It's Caunter
- 3:34Speaker 1: Fitzgerald too. You have Howard Lutnix firm and firm. It's
- 3:38Speaker 1: really fascinating to see. Yeah, Maderna and then other biotech
- 3:42Speaker 1: and vaccine makers got a hit today for.
- 3:44Speaker 3: Sure, sped as well.
- 3:46Speaker 2: All right, good stuff as always the Stock Movers podcast
- 3:51Speaker 2: from Bloomberg Radio. Check back with us throughout today for
- 3:54Speaker 2: the latest roundup of companies making news on Wall Street
- 3:58Speaker 2: and for the latest market moving lines. Listen to Bloomberg
- 4:01Speaker 2: Radio Live, catch us on YouTube, Bloomberg dot com, and
- 4:05Speaker 2: on Applecarplay and Android Auto with the Bloomberg Business app.